Compare FNWD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | CHRS |
|---|---|---|
| Founded | 1994 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.1M | 159.1M |
| IPO Year | 1996 | 2014 |
| Metric | FNWD | CHRS |
|---|---|---|
| Price | $42.49 | $1.04 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 7.0K | ★ 1.4M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.14% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.81 | $44.19 |
| Revenue Next Year | $5.26 | $65.06 |
| P/E Ratio | $42.13 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.05 | $0.94 |
| 52 Week High | $45.90 | $2.62 |
| Indicator | FNWD | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 60.29 | 42.70 |
| Support Level | $42.56 | $0.97 |
| Resistance Level | $44.01 | $1.53 |
| Average True Range (ATR) | 0.79 | 0.07 |
| MACD | 0.20 | 0.00 |
| Stochastic Oscillator | 100.00 | 46.68 |
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.